93 related articles for article (PubMed ID: 24957113)
1. Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.
Nakai N; Katoh N
Allergol Int; 2014 Sep; 63(3):489-91. PubMed ID: 24957113
[No Abstract] [Full Text] [Related]
2. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Tanaka K; Ogawa Y; Shimada S
J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
[No Abstract] [Full Text] [Related]
3. Severe leucopenia associated with Sitagliptin use.
Pitocco D; Zaccardi F; Martini F; Scavone G; Musella T; Caputo S; Ghirlanda G
Diabetes Res Clin Pract; 2011 Feb; 91(2):e30-2. PubMed ID: 21035885
[TBL] [Abstract][Full Text] [Related]
4. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
5. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Stricklin SM; Stoecker WV; Rader RK; Hood AF; Litt JZ; Schuman TP
Dermatol Online J; 2012 Feb; 18(2):9. PubMed ID: 22398230
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
8. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin intolerance.
Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
[No Abstract] [Full Text] [Related]
10. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
11. New treatment for diabetes.
FDA Consum; 2007; 41(1):3. PubMed ID: 17342826
[No Abstract] [Full Text] [Related]
12. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
13. Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Mas-Vidal A; Santos-Juanes J; Esteve-Martinez A; Caminal-Montero L; Coto-Segura P
Australas J Dermatol; 2012 Feb; 53(1):70-2. PubMed ID: 22309337
[TBL] [Abstract][Full Text] [Related]
14. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
[No Abstract] [Full Text] [Related]
15. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
Karlsson EA; Palmér M; Malmström R
Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
[No Abstract] [Full Text] [Related]
16. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
18. [Sitagliptine (Januvia)].
Duh D; Vandevijver A
J Pharm Belg; 2008 Mar; 63(1):31-2. PubMed ID: 18479082
[No Abstract] [Full Text] [Related]
19. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
20. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
Desai S; Brinker A; Swann J; Iyasu S
Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
